Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System

Acquisition of IFM Therapeutics subsidiary gives Novartis full rights to one clinical and two pre-clinical NLRP3 antagonist programs NLRP3 inhibition offers novel approach to preventing chronic inflammation that drives serious disease IFM to receive ... Biopharmaceuticals, Mergers & Acquisitions IFM Therapeutics, Novartis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news